The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer
Abstract
BACKGROUND: In the prostate, conversion of testosterone to dihydrotestosterone (DHT), by the enzymes 5α‐reductase types 1 and 2 (5αR1, 5αR2) is required for normal growth and probably also for development of prostate cancer (PCa). Finasteride, a 5αR2 inhibitor, was shown to reduce the prevalence of PCa in the Prostate Cancer Prevention Trial. However, inhibition of both 5αR isoenzymes causes a greater decrease in serum DHT. The aim of this study was to assess differential expression of these enzymes at various stages of PCa development. METHODS: Immunostaining for 5αR1 and 5αR2, using specific, well‐validated antibodies, was evaluated in 26 benign prostatic hyperplasia (BPH) (16 for 5αR2), 53 primary PCa (21 for 5αR2), 18 prostatic intraepithelial neoplasia (PIN), 12 primary PCa treated with neoadjuvant androgen ablation, 15 locally recurrent PCa specimens, and 18 PCa metastases. RESULTS: The mean area of moderate plus high intensity staining for 5αR1 increased from 4.8 ± 2.8% of total epithelial area in BPH, to 18.9 ± 5.7% in PIN, 17.0 ± 3.2% in primary cancer, 38.0 ± 7.3% in recurrent cancer, and 55.8 ± 8.5% in PCa metastases. The mean staining area for 5αR2 decreased from 58.8 ± 7.2% in BPH, to 21.1 ± 5.5% in PIN and 34.8 ± 6.7% in primary PCa. Staining for 5αR2 was increased in recurrent cancer and PCa metastases compared to primary PCa, at 58.7 ± 5.2% and 69.2 ± 8.7%, respectively. CONCLUSIONS: 5αR1 immunostaining is increased and 5αR2 immunostaining is decreased during development of PCa. In addition, there is increased expression of both 5αR isozymes in recurrent and metastatic cancers, suggesting that both isozymes may be important in the development and progression of PCa. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Current State of Hormonal Therapy for Prostate Cancer
Hellerstedt, B. A., & Pienta, K. J. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.3.154 · Cited by 386
Cited by
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Effect of Dutasteride on the Risk of Prostate Cancer
Andriole, G. L., Bostwick, D. G., Brawley, O. W., Gomella, L. G., Marberger, M., Montorsi, F., Pettaway, C. A., Tammela, T. L., Teloken, C., Tindall, D. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908127 · Cited by 1,152
Self-citationStanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases
Azzouni, F., Godoy, A., Li, Y., & Mohler, J. (2012) · Advances in Urology · doi:10.1155/2012/530121 · Cited by 333
Metadata
- Authors
- Thomas, L. N., Lazier, C. B., Gupta, R., Norman, R. W., Troyer, D. A., O'Brien, S. P., & Rittmaster, R. S.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2005-03-24
- Volume
- 63
- Issue
- 3
- Pages
- 231-239
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2040556993
- Cited by
- 179
- References
- 1
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.